Back to Nova Southeastern University
Saturday, August 23, 2025, 8 a.m. to 5 p.m. (EST)
Join Live Zoom Sessions from Anywhere in the World
Click Here to Register for the Conference
About the Cancer Therapies Conference
This twelve-hour program exhibits a non-traditional cancer clinical practice presentation. Cancer Therapies 2025 offers both a treatment guide for twenty different cancers and a patient clinical outcome review based upon their treatments.
The emphasis of this unique seminar is on assessing the hallmarks of cancer, environmental risk factors, diagnostic tools, and comprehensive treatment protocols that target tumor microenvironment and cancer root causes. You will learn how to use repurposed drugs and natural substances via oral and IV routes for these top cancers seen in practice.
Unlike traditional cancer presentations, this presentation will address the elephants in the room, the hallmarks of cancer, mitochondrial dysfunction, and circulating tumor cells.
The first part of Cancer Therapies 2025 is an exclusive home study (video) format that focuses on the highlights from each of the four previous lectures (2021, 2022, 2023, 2024) given by Dr. Ghen. These videos will provide pertinent background for this final chapter that will bring clinical clarity to a complex subject, curing cancer.
The ”war on cancer” was launched in 1971 by President Richard Nixon to find a cure for cancer through increased research. The goals were to improve the understanding of cancer biology and to develop more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death.
National Cancer Act of 1971. National Cancer Institute.
In our fifth year, we’re diving deeper into the hallmarks of cancer, mitochondrial dysfunction, and circulating tumor cells.
You’ll learn how to interpret advanced diagnostics, including circulating tumor cells, and appreciate personalized treatment plans using natural substances, repurposed drugs, and non-toxic therapies, including IV Vitamin C, DCA, NAD, hyperbaric oxygen, infrared light, ozone, and so much more.
"This course bridges cutting-edge science with real-world application. You’ll study nutritional strategies, mitigate treatment side effects, and join in therapies that enhance patient quality of life while addressing drug resistance and immune suppression." Mitch Ghen, D.O., Ph.D.
Pre-Course Home Study
Learners will be able to:
-
Review the Warburg Effect and cancer as a metabolic disease.
-
Describe a new approach to addressing cancer as a metabolic disease.
-
Identify cancer pathophysiology, including the hallmarks of cancer, mitochondrial dysfunction, cancer stem cells, metabolic pathways, and the tumor microenvironment.
-
Describe the shortcomings and adverse impacts of standard treatments (chemotherapy, radiation) and compare them with emerging integrative modalities, including repurposed pharmaceuticals and natural compounds.
-
Explain comprehensive blood markers, advanced diagnostics (e.g., circulating tumor cells, WBC phenotyping), and radiologic findings to guide therapeutic decision-making.
-
Discuss cancer markers.
Live Webinar
Learners will be able to:
-
Classify individualized, multi-modal treatment plans utilizing IV therapies (Vitamin C, ALA, DCA, NAD, etc.), hyperthermia, HBOT, photodynamic therapy, mistletoe, and other non-toxic approaches, integrating them synergistically with or as alternatives to conventional therapies.
-
Recognize the safe, effective, and evidence-informed use of repurposed drugs (e.g., metformin, mebendazole, doxycycline) and natural substances to mitigate complications (e.g., pain, nausea, cachexia, mucositis), reduce inflammation, and target drug resistance and immune suppression.
-
Explain nutritional strategies, including anti-inflammatory and immune-supportive diets, to modulate cancer progression and support systemic recovery.
-
Arrange clinical research, case studies, and experimental insights into daily practice to support ongoing protocol refinement and innovation.
-
List long-term follow-up strategies, including monitoring CTC trends, metabolic markers, and treatment response benchmarks, to continually adjust and optimize care protocols for different types of cancer.
This accredited activity was planned and designed for pharmacy practitioners who are dedicated to patient care.
Pharmacists need to advance their knowledge and skills in non-traditional cancer treatment, the prevention and treatment of potential adverse effects, and become patient advocates for those who choose an integrative oncology alternative.
Program Fee
-
$195 for General CE Credits and/or Consultant Recertification Credits
Registration
Additional Information
-
Participants will receive the home study video information after registration.
A refund can be requested in an e-mail format (send an email to carsten@nova.edu).
Prior to Saturday May 3rd, 2025 your registration fee less $15.00 will be credited to the same card.
The goal of this program is to provide attendees with the most current non-traditional treatment knowledge and methods (through clinical patient assessments) that address the most common types of cancer.
With this understanding, it becomes a secondary goal of the program to provide pharmacists with the knowledge and exact tools of inexpensive drugs and natural products, and the dosing schedules to support physicians, patients, and patient advocates with the ability to eliminate cancer stem cells and extend the cancer patient’s quality of life.
Cancer Therapies 2025
Saturday, August 23, 2025
Integrative Oncology: Targeting Vance Hallmarks, Metabolic Pathways, & Circulating Tumor Cells with Multimodal Therapies. The Key to Success.
| Time | Activity |
|---|---|
|
8:00 a.m. |
Connect live to NSU via Zoom; course introduction and program overview with Mitch Ghen, D.O., Ph.D. |
|
8:05 a.m. |
Objectives of integrative oncology:
|
|
9:50 a.m. |
Morning break |
|
10:00 a.m. |
Targeting cancer hallmarks and metabolic pathways; circulating tumor cells; treating mitochondrial dysfunction. |
|
12:10 p.m. |
Lunch break (vendor showcase optional) |
|
1:00 p.m. |
Innovative treatment modalities, including:
|
|
2:00 p.m. |
Management of common complaints and mitigation of side effects of conventional therapies:
|
|
3:00 p.m. |
Afternoon break |
|
3:10 p.m. |
Development of integrative cancer protocols; clinical case reviews; treatment protocols for specific cancer types. |
|
5:10 p.m. |
Course adjournment |
Mitch Ghen, D.O., Ph.D., M.S., Integrative Medicine Physician, Author, Radio Host, Private Practice, Boca Raton, FL
All program committee members, reviewers, faculty presenters and technology support staff involved in the planning and delivery of this accredited continuing pharmacy education activity have no relevant financial relationships with ineligible companies to disclose.
NSU College of Pharmacy is the sponsor for this activity and continues the practice of not accepting commercial support for any of its continuing pharmacy educational activities.
Dr. Mitch Ghen addresses that he has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
The program reviewer, Kavita R. Singh, Pharm.D., states that she has no financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
Both Irena Ghen, APRN (layout designer) and Carsten Evans, Ph.D. (program administrator), as well as, IT managers Jacob Johnson, Pharm.D., and Emmanuel Escobar Pharm.D., who are all in positions to influence the content of this activity, all state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity.
Accreditation
Nova Southeastern University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of Continuing Pharmacy Education.This program is approved for 12.0 contract hours (1.2 CEUs) of continuing pharmacy education credits. This is a Knowledge Based activity.
For pharmacists to obtain course credit they must register for the course, provide an e-mail identity at the beginning of Saturdays’ meeting when coming into the classroom on Zoom, answer any questions presented by the speaker, answer the evaluation request and fill out the “Certification of Participation” that acknowledges their type and number of credits being requested. A correct ePID# and Birth Month, and Birth Day must be provided.
The provider will post all successful credits by August 30, 2025. Participants are responsible for ensuring that their credits are posted. Credits should be verified by the participant no later than September 23, 2025.
For the State of Florida, this program has been approved for both General Pharmacist and Consultant Re-Certification credits. Pharmacists can achieve up to 12 general or consultant recertification hours, or any combination of either.
All earned continuing pharmacy education (CPE) credits for this program will be reported to CE Broker for those pharmacists who review the pre-course videos and attend the live presentation hours for which they have requested credit, be actively engaged via chat, e-mail, or live interaction, answer any presenter questions, complete and submit the course evaluation for Saturday August 23, 2025, as well as submitting the Certification of Participation (the document that you request your hours of attendance and your signature of attestation. Pharmacists must also provide their correct license numbers.
The provider will post all successful credits by August 30, 2025. Participants are responsible for ensuring that their credits are posted.
**Pharmacists should verify (in their CE Broker profiles) their credits earned no later than September 23, 2025, as CE Broker allows only 30 days after a program for a provider to report credits.
Policy of Non-Discrimination
Nova Southeastern University admits students of any race, color, sex, sexual orientation, age, non-disqualifying disability, religion or creed, or national or ethnic origin to all the rights, privileges, programs, and activities generally accorded or made available to students at the school, and does not discriminate in administration of its educational policies, admissions policies, scholarship and loan programs, and athletic and other school-administered programs.